CpG improves influenza vaccine efficacy in young adult but not aged mice

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Ramirez, Alejandro ^a,b   Co, Mary ^d   Mathew, Anuja ^a,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b IQUR LTD   (United Kingdom)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN G; INFLUENZA VACCINE; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; OLIGODEOXYRIBONUCLEOTIDE; VIRUS ANTIBODY;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INNATE IMMUNITY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; YOUNG ADULT; AGE; AGING; ANIMAL; ANTIGEN PRESENTATION; BLOOD; C57BL MOUSE; DENDRITIC CELL; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INTRANASAL DRUG ADMINISTRATION; MACROPHAGE; MALE; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PRIMARY CELL CULTURE; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AGE FACTORS; AGING; ANIMALS; ANTIBODIES, VIRAL; ANTIGEN PRESENTATION; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE INFECTIONS; PRIMARY CELL CULTURE; VACCINATION; VACCINES, INACTIVATED;

EID: 84962495233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150425     Document Type: Article

References (43)

1. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to influenza and RSVinthe United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza and other respiratory viruses. 2014; 8(5):507-15. Epub 2014/07/01. doi: 10.1111/irv.12258 PMID: 24975705; PubMed Central PMCID: PMC4181813.
2. Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. The Lancet Infectious diseases. 2015; 15 (3):293-300. Epub 2015/02/13. doi: 10.1016/S1473-3099(14)71087-4 PMID: 25672568.
3. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. The Journal of clinical investigation. 2011; 121(8):3109-19. Epub 2011/07/26. doi: 10.1172/JCI57834 PMID: 21785218; PubMed Central PMCID: PMC3148747.
4. Saurwein-Teissl M, Steger MM, Gluck R, Cryz S, Grubeck-Loebenstein B. Influenza vaccination in a healthy geriatric population: preferential induction of antibodies specific for the H3N2 influenza strain despite equal T cell responsiveness to all vaccine strains. Vaccine. 1998; 16(2-3):196-200. Epub 1998/06/02. PMID: 9607030.
5. Segerstrom SC, Schipper LJ, Greenberg RN. Caregiving, repetitive thought, and immune response to vaccination in older adults. Brain, behavior, and immunity. 2008; 22(5):744-52. Epub 2008/01/02. doi: 10.1016/j.bbi.2007.11.004 PMID: 18166335; PubMed Central PMCID: PMC2464708.
6. Shen-Orr SS, Furman D. Variability in the immune system: of vaccine responses and immune states. Current opinion in immunology. 2013; 25(4):542-7. Epub 2013/08/21. doi: 10.1016/j.coi.2013.07.009 PMID: 23953808; PubMed Central PMCID: PMC3788704.
7. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007; 25(16):3066-9. PMID: 17275144.
8. Lang PO, Govind S, Mitchell WA, Siegrist CA, Aspinall R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing research reviews. 2011; 10 (3):389-95. Epub 2010/10/05. doi: 10.1016/j.arr.2010.09.005 PMID: 20888439.
9. Agrawal A, Gupta S. Impact of aging on dendritic cell functions in humans. Ageing research reviews. 2011; 10(3):336-45. Epub 2010/07/14. doi: 10.1016/j.arr.2010.06.004 PMID: 20619360; PubMed Central PMCID: PMC3030666.
10. Aspinall R, Govind S, Lapenna A, Lang PO. Dose response kinetics of CD8 lymphocytes from young animals transfused into old animals and challenged with influenza. Immunity & ageing: I & A. 2013; 10 (1):34. Epub 2013/08/21. doi: 10.1186/1742-4933-10-34 PMID: 23947636; PubMed Central PMCID: PMC3765176.
11. Avelino-Silva VI, Ho YL, Avelino-Silva TJ, Santos Sde S. Aging and HIV infection. Ageing research reviews. 2011; 10(1):163-72. Epub 2010/10/27. doi: 10.1016/j.arr.2010.10.004 PMID: 20974294.
12. Aydar Y, Balogh P, Tew JG, Szakal AK. Follicular dendritic cells in aging, a "bottle-neck" in the humoral immune response. Ageing research reviews. 2004; 3(1):15-29. Epub 2004/05/28. doi: 10.1016/j.arr. 2003.08.002 PMID: 15163101.
13. Beli E, Clinthorne JF, Duriancik DM, Hwang I, Kim S, Gardner EM. Natural killer cell function is altered during the primary response of aged mice to influenza infection. Mechanisms of ageing and development. 2011; 132(10):503-10. Epub 2011/09/07. doi: 10.1016/j.mad.2011.08.005 PMID: 21893080; PubMed Central PMCID: PMC3185116.
14. Boraschi D, Aguado MT, Dutel C, Goronzy J, Louis J, Grubeck-Loebenstein B, et al. The gracefully aging immune system. Science translational medicine. 2013; 5(185):185ps8. Epub 2013/05/17. doi: 10.1126/scitranslmed.3005624 PMID: 23677590.
15. Effros RB, Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? 1997; 18(9):450-4.
16. Higashimoto Y, Fukuchi Y, Shimada Y, Ishida K, Ohata M, Furuse T, et al. The effects of aging on the function of alveolar macrophages in mice. Mechanisms of ageing and development. 1993; 69(3):207-17. Epub 1993/07/01. PMID: 8412370.
17. Jiang J, Bennett AJ, Fisher E, Williams-Bey Y, Shen H, Murasko DM. Limited expansion of virus-specific CD8 T cells in the aged environment. Mechanisms of ageing and development. 2009; 130(11-12):713-21. Epub 2009/09/12. doi: 10.1016/j.mad.2009.08.007 PMID: 19744506; PubMed Central PMCID: PMC2839881.
18. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. ExpGerontol. 2004; 39 (5):687-99.
19. Bordon J, Aliberti S, Fernandez-Botran R, Uriarte SM, Rane MJ, Duvvuri P, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2013; 17(2):e76-83. Epub 2012/10/17. doi: 10.1016/j.ijid.2012.06.006 PMID: 23069683.
20. Appay V, Sauce D. Naive T cells: the crux of cellular immune aging? Experimental gerontology. 2014; 54:90-3. Epub 2014/01/21. doi: 10.1016/j.exger.2014.01.003 PMID: 24440387.
21. Salam N, Rane S, Das R, Faulkner M, Gund R, Kandpal U, et al. Tcell ageing: effects of age on development, survival & function. The Indian journal of medical research. 2013; 138(5):595-608. Epub 2014/01/18. PMID: 24434315; PubMed Central PMCID: PMC3928693.
22. Blackman MA, Woodland DL. The narrowing of the CD8 Tcell repertoire in old age. Current opinion in immunology. 2011; 23(4):537-42. Epub 2011/06/10. doi: 10.1016/j.coi.2011.05.005 PMID: 21652194; PubMed Central PMCID: PMC3163762.
23. Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J, et al.T cells and aging, January 2002 update. Frontiers in bioscience: ajournal and virtual library. 2002; 7:d1056-183. Epub 2002/05/07. PMID: 11991846.
24. Martin JT. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals: journal of the International Association of Biological Standardization. 1997; 25 (2):209-13. Epub 1997/06/01. doi: 10.1006/biol.1997.0086 PMID: 9236054.
25. Reisinger KS, Holmes SJ, Pedotti P, Arora AK, Lattanzi M. A dose-ranging study of MF59((R))-adju-vanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Human vaccines &immunotherapeutics. 2014; 10(8):2395-407. Epub 2014/11/27. doi: 10.4161/hv.29393 PMID: 25424947.
26. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009; 200(2):172-80. doi: 10.1086/599790 PMID: 19508159.
27. Pica N, Langlois RA, Krammer F, Margine I, Palese P. NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge. J Virol. 2012; 86(19):10293-301. doi: 10.1128/JVI.01131-12 PMID: 22787224; PubMed Central PMCID: PMCPMC3457311.
28. Schneider-Ohrum K, Giles BM, Weirback HK, Williams BL, DeAlmeida DR, Ross TM. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine. 2011; 29(48):9081-92. Epub 2011/10/04. doi: 10.1016/j.vaccine.2011.09.051 PMID: 21963872.
29. Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. Journal of virology. 2011; 85(1):217-30. Epub 2010/10/29. doi: 10.1128/JVI.01805-10 PMID: 20980507; PubMed Central PMCID: PMC3014161.
30. Fujihashi K, Sato S, Kiyono H. Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly. Experimental gerontology. 2014; 54:21-6. Epub 2014/01/21. doi: 10.1016/j.exger.2014.01. 006 PMID: 24440991; PubMed Central PMCID: PMC3989367.
31. Ramirez A, Rathinam V, Fitzgerald KA, Golenbock DT, Mathew A. Defective pro-IL-1beta responses in macrophages from aged mice. Immunity & ageing: I & A. 2012; 9(1):27. Epub 2012/12/12. doi: 10.1186/1742-4933-9-27 PMID: 23228123; PubMed Central PMCID: PMC3545921.
32. Panda A, Qian F, Mohanty S, van Duin D, Newman FK, Zhang L, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. Journal of immunology. 2010; 184(5):2518-27. Epub 2010/01/27. doi: 10.4049/jimmunol.0901022 PMID: 20100933; PubMed Central PMCID: PMC3867271.
33. Toapanta FR, Ross TM. Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res. 2009; 10:112. doi: 10.1186/1465-9921-10-112 PMID: 19922665; PubMed Central PMCID: PMC2785782.
34. Liu WM, Nahar TE, Jacobi RH, Gijzen K, van Beek J, Hak E, et al. Impaired production of TNF-alpha by dendritic cells of older adults leads to a lower CD8+ T cell response against influenza. Vaccine. 2012; 30(9):1659-66. Epub 2012/01/11. PMID: 22230585.
35. Xu T, Qiao J, Zhao L, Wang G, He G, Li K, et al. Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. American journal of respiratory and critical care medicine. 2006; 174 (9):1011-7. Epub 2006/08/19. doi: 10.1164/rccm.200511-1751OC PMID: 16917113.
36. Liu WM, van derZeijst BA, Boog CJ, Soethout EC. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum Vaccin. 2011; 7 Suppl:94-8. PMID: 21301210.
37. van Duin D, Shaw AC. Toll-like receptors in older adults. Journal of the American Geriatrics Society. 2007; 55(9):1438-44. Epub 2007/09/05. doi: 10.1111/j.1532-5415.2007.01300.x PMID: 17767688.
38. Frasca D, Diaz A, Romero M, Landin AM, Phillips M, Lechner SC, et al. Intrinsic defects in Bcell response to seasonal influenza vaccination in elderly humans. Vaccine. 2010; 28(51):8077-84. Epub 2010/10/27. doi: 10.1016/j.vaccine.2010.10.023 PMID: 20974306; PubMed Central PMCID: PMC3223387.
39. de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. The Journal of infectious diseases. 1999; 179(1):31-6. Epub 1998/12/08. doi: 10.1086/314540 PMID: 9841819.
40. DellaCioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, et al. Superior immuno-genicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults. Human vaccines &immunotherapeutics. 2012; 8(2):216-27. Epub 2012/03/20. doi: 10.4161/hv.18445 PMID: 22426371.
41. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert opinion on biological therapy. 2010; 10(4):639-51. Epub 2010/03/12. doi: 10.1517/14712591003724662 PMID: 20218923.
42. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009; 27(45):6291-5. PMID: 19840662.
43. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert review of vaccines. 2008; 7(4):467-79. Epub 2008/05/01. doi: 10.1586/14760584.7.4.467 PMID: 18444893.